Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2019.
Adolescent
Adult
Aged
Aged, 80 and over
Australia
Child
Child, Preschool
Disease Notification
Humans
Infant
Infant, Newborn
Middle Aged
Pneumococcal Infections
/ epidemiology
Pneumococcal Vaccines
/ administration & dosage
Population Surveillance
Serogroup
Streptococcus pneumoniae
/ classification
Time Factors
Young Adult
Journal
Communicable diseases intelligence (2018)
ISSN: 2209-6051
Titre abrégé: Commun Dis Intell (2018)
Pays: Australia
ID NLM: 101735394
Informations de publication
Date de publication:
18 May 2020
18 May 2020
Historique:
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
The number of notified cases of invasive pneumococcal disease (IPD) in the third quarter of 2019 was higher than in the previous quarter, but lower than in the third quarter of 2018. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV), and also those serotypes not covered by any available vaccine, has been increasing steadily across all age groups.
Identifiants
pubmed: 32418512
doi: 10.33321/cdi.2020.44.40
doi:
Substances chimiques
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Commonwealth of Australia CC BY-NC-ND.